Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease

Completed

Conditions: Liver Disease
Fatty Liver

First Posted Date: 2015-08-13

Last Posted Date: 2025-06-10

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 53

Registration Number: NCT02520609

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: Advanced Lung Non-Squamous Non-Small Cell Carcinoma
Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
Stage III Lung Non-Small Cell Cancer AJCC v7
Stage IV Lung Non-Small Cell Cancer AJCC v7
Stage IIIA Lung Non-Small Cell Cancer AJCC v7

Interventions: Drug: Navitoclax
Drug: Osimertinib

First Posted Date: 2015-08-13

Last Posted Date: 2024-08-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 27

Registration Number: NCT02520778

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

and more 15 locations

Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir

Phase 2

Completed

Conditions: Hepatitis D

Interventions: Drug: Lonafarnib
Drug: Ritonavir
Other: Placebo

First Posted Date: 2015-07-30

Last Posted Date: 2018-09-25

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 22

Registration Number: NCT02511431

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

Phase 3

Active, not recruiting

Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8
Metastatic Non-Cutaneous Melanoma
Recurrent Cutaneous Melanoma
Recurrent Mucosal Melanoma
Clinical Stage III Cutaneous Melanoma AJCC v8
Metastatic Cutaneous Melanoma
Metastatic Mucosal Melanoma
Recurrent Non-Cutaneous Melanoma
Non-Cutaneous Melanoma

Interventions: Procedure: Biospecimen Collection
Procedure: Computed Tomography
Biological: Ipilimumab
Biological: Pembrolizumab
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
Other: Quality-of-Life Assessment
Biological: Recombinant Interferon Alfa-2b

First Posted Date: 2015-07-23

Last Posted Date: 2025-05-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1301

Registration Number: NCT02506153

Locations: 🇺🇸
Ephrata Cancer Center, Ephrata, Pennsylvania, United States
🇺🇸
Ephrata Community Hospital, Ephrata, Pennsylvania, United States
🇺🇸
UPMC Hillman Cancer Center Erie, Erie, Pennsylvania, United States

and more 575 locations

Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer

Phase 2

Terminated

Conditions: Birt-Hogg-Dube Syndrome
Renal Cancer

Interventions: Drug: Everolimus

First Posted Date: 2015-07-22

Last Posted Date: 2019-03-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3

Registration Number: NCT02504892

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: Metastatic Lung Non-Small Cell Carcinoma
Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Stage IV Lung Non-Small Cell Cancer AJCC v7
Stage III Lung Non-Small Cell Cancer AJCC v7
Recurrent Lung Non-Small Cell Carcinoma
Stage IIIA Lung Non-Small Cell Cancer AJCC v7

Interventions: Other: Laboratory Biomarker Analysis
Drug: Osimertinib
Other: Pharmacological Study
Drug: Sapanisertib

First Posted Date: 2015-07-21

Last Posted Date: 2025-06-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT02503722

Locations: 🇺🇸
Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇨🇦
BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada

and more 2 locations

Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Phase 1

Completed

Conditions: Metastatic Malignant Solid Neoplasm
Advanced Malignant Solid Neoplasm
Unresectable Solid Neoplasm

Interventions: Drug: CDK Inhibitor AT7519
Other: Laboratory Biomarker Analysis
Drug: Onalespib
Other: Pharmacological Study

First Posted Date: 2015-07-21

Last Posted Date: 2025-02-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 29

Registration Number: NCT02503709

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

and more 3 locations

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

Phase 2

Active, not recruiting

Conditions: Fallopian Tube Clear Cell Adenocarcinoma
Fallopian Tube Endometrioid Adenocarcinoma
Fallopian Tube Serous Adenocarcinoma
Fallopian Tube Transitional Cell Carcinoma
Fallopian Tube Undifferentiated Carcinoma
Ovarian Clear Cell Adenocarcinoma
Ovarian Endometrioid Adenocarcinoma
Ovarian Seromucinous Carcinoma
Ovarian Serous Adenocarcinoma
Ovarian Transitional Cell Carcinoma

Interventions: Procedure: Computed Tomography
Drug: Cediranib
Procedure: Magnetic Resonance Imaging
Drug: Cediranib Maleate
Drug: Paclitaxel
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
Other: Questionnaire Administration
Drug: Olaparib
Drug: Topotecan
Drug: Topotecan Hydrochloride

First Posted Date: 2015-07-20

Last Posted Date: 2025-05-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 582

Registration Number: NCT02502266

Locations: 🇺🇸
Sutter Roseville Medical Center, Roseville, California, United States
🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Alaska Women's Cancer Care, Anchorage, Alaska, United States

and more 395 locations

Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery

Phase 2

Completed

Conditions: Locally Advanced Bone Sarcoma
Metastatic Liposarcoma
Locally Advanced Gastrointestinal Stromal Tumor
Pleomorphic Liposarcoma
Stage III Soft Tissue Sarcoma AJCC v7
Locally Advanced Dedifferentiated Liposarcoma
Locally Advanced Soft Tissue Sarcoma
Metastatic Unresectable Sarcoma
Unresectable Liposarcoma
Metastatic Soft Tissue Sarcoma

Interventions: Biological: Ipilimumab
Other: Laboratory Biomarker Analysis
Biological: Nivolumab
Other: Quality-of-Life Assessment

First Posted Date: 2015-07-17

Last Posted Date: 2023-10-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 164

Registration Number: NCT02500797

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

and more 645 locations

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

Phase 2

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm
Metastatic Pancreatic Adenocarcinoma
Metastatic Triple-Negative Breast Carcinoma
Stage III Breast Cancer AJCC v7
Stage III Lung Small Cell Carcinoma AJCC v7
Stage IIIA Breast Cancer AJCC v7
Stage IIIC Breast Cancer AJCC v7
Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Stage IV Lung Non-Small Cell Cancer AJCC v7
Triple-Negative Breast Carcinoma

Interventions: Other: 18F-Fluoromisonidazole
Drug: Cediranib Maleate
Other: Laboratory Biomarker Analysis
Drug: Olaparib
Procedure: Positron Emission Tomography

First Posted Date: 2015-07-15

Last Posted Date: 2025-05-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 122

Registration Number: NCT02498613

Locations: 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸
Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States
🇺🇸
Weisberg Cancer Treatment Center, Farmington Hills, Michigan, United States

and more 13 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy